Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$3.13 USD
+0.21 (7.19%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.13 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
Brokerage Reports
Aprea Therapeutics, Inc. [APRE]
Reports for Purchase
Showing records 1 - 20 ( 67 total )
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology-Monthly Check-Up- September 2024
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Results; Pipeline Continues to Advance; ACESOT-1051 Phase 1 Data Expected 1H25
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; ABOYA-119 Data in 1H:25, ACESOT-1051 Ph 1 Initiated
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOLs Support Differentiated APR-1051 Safety and Potency Profile; Next Clinical Update By YE24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Phase 1 Study Evaluating APR-1051 in Advanced Solid Tumors; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Duo of Oncology Assets Advance Through the Clinic; Initial Efficacy Data as Early as 2H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; ATRN-119 Data in 2H:24, APR-1051 Ph 1 Set to Initiate in June
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updates Across Programs at AACR Highlight Growing DDRFocused Oncology Pipeline; Welcome ATRN-333 to the Mix
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; Synthetic Lethality Based Pipeline Looks to Build Momentum Throughout 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AACR 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Focus on Clinical Execution Across DDR-Based Pipeline In the Year Ahead; ATRN-119 Phase 2 RP2D Expected 2H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provides Corporate Updates for ATRN-119 and APR-1051
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Synthetic Lethality''s Profile is on the Rise; ATRN-1051 IND Submission by YE23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J